Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in the Journal of the American Academy of Dermatology (JAAD) demonstrating that its AdvanceAD-Tx test can identify patients with moderate-to-severe atopic dermatitis (AD) who are significantly more likely to achieve greater and faster clinical responses when treated with a Janus kinase inhibitor (JAKi) compared to T helper type 2 (Th2)-targeted therapies.1 “Atopic dermatitis can look similar on the surface, but the biology driving the disease can differ meaningfully from patient to patient,” said Mark G. Lebwohl, M.D.

GlobeNewsWire • Feb 19, 2026

Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Castle Biosciences (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 19, 2026

Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Castle Biosciences (CSTL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research • Feb 9, 2026

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m.

GlobeNewsWire • Feb 5, 2026

Wasatch Micro Cap Fund Q4 2025 Performance Review

Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and paninis, Mama's targets the deli area of grocery stores and warehouse clubs. On the downside, software distribution company Climb Global Solutions, Inc. was the Fund's leading laggard in the quarter.

Seeking Alpha • Feb 4, 2026

Allspring Emerging Growth Fund Q4 2025 Performance Review

After years of underinvestment and production delays across the aerospace industry, ATI is now capitalizing on a surge in demand fueled by Boeing and Airbus' historically large backlogs for new aircraft.

Seeking Alpha • Feb 4, 2026

Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jan 23, 2026

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025. “We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.

GlobeNewsWire • Jan 11, 2026

Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus

Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.

Zacks Investment Research • Dec 29, 2025

What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'

Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Investment Research • Dec 24, 2025